JPMorgan, RBC Capital and Canaccord Genuity assist with financing
By Toni Weeks
San Diego, Jan. 17 - AVEO Pharmaceuticals, Inc. said it priced a $50 million public offering of common stock with a $7.5 million greenshoe. The offering was announced on Wednesday.
The company will sell 6,667,000 common shares at $7.50 per share. The price per share is a 7.64% discount to the Jan. 16 closing share price of $8.12.
J.P. Morgan Securities LLC is the bookrunning manager. RBC Capital Markets, LLC and Canaccord Genuity Inc. are co-lead managers.
Settlement is expected on Jan. 23.
AVEO is a Cambridge, Mass.-based biopharmaceutical company that is developing cancer therapeutics.
| Issuer: | AVEO Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $50,002,500
|
| Greenshoe: | $7,500,375
|
| Shares: | 6,667,000
|
| Price: | $7.50
|
| Warrants: | No
|
| Bookrunner: | J.P. Morgan Securities LLC
|
| Co-lead managers: | RBC Capital Markets, LLC and Canaccord Genuity Inc.
|
| Announcement date: | Jan. 16
|
| Pricing date: | Jan. 17
|
| Settlement date: | Jan. 23
|
| Stock symbol: | Nasdaq: AVEO
|
| Stock price: | $8.12 at close Jan. 16
|
| Market capitalization: | $338.03 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
